Picture 1 of 1

Stock photo

Levodopa and Carbidopa Controlled Release Matrix Tablets by Jagan Mohan Somagoni - Picture 1 of 1

Levodopa and Carbidopa Controlled Release Matrix Tablets by Jagan Mohan Somagoni, Y. Madhusudan Rao and V. Kishan (2010, Trade Paperback)

AlibrisBooks (464407)

98.6% positive feedback

Price:

$56.77

Free shipping

Estimated delivery Tue, Sep 2 - Mon, Sep 8

Returns:

30 days returns. Buyer pays for return shipping. If you use an eBay shipping label, it will be deducted from your refund amount.

Condition:

Brand New

New Trade paperback

About this product

Product Identifiers

PublisherLAP Gmbh & Company KG

ISBN-103838348117

ISBN-139783838348117

eBay Product ID (ePID)124305619

Product Key Features

Number of Pages72 Pages

LanguageEnglish

Publication NameLevodopa and Carbidopa Controlled Release Matrix Tablets

SubjectGeneral

Publication Year2010

TypeTextbook

Subject AreaMedical

AuthorJagan Mohan Somagoni, Y. Madhusudan Rao, V. Kishan

FormatTrade Paperback

Dimensions

Item Height0.2 in

Item Weight4.2 Oz

Item Length9 in

Item Width6 in

Additional Product Features

SynopsisIn recent years, in association with progress and innovation in the field of pharmaceutical technology, there has been an increasing effort to develop prolonged release dosage forms for many drugs. Correspondingly, a growing number of new prolonged release dosage forms have been submitted for regulatory approval. Prolonged release dosage forms have many advantages in safety and efficacy over immediate release drug products in that the frequency of dosing can be reduced, drug efficacy can be prolonged and the incidence and/or intensity of adverse effects can be decreased. However, some prolonged release dosage forms have less clear rationale or are developed for active ingredients which are not appropriate for prolonged release dosage forms. In other cases, prolonged release dosage forms are designed without full consideration of the basic properties of the drugs. Moreover, standards for dissolution tests, which are important for evaluating prolonged release dosage forms, have not appropriately been established. As a result, it is often difficult to evaluate whether a prolonged release dosage form is acceptable or not.